INV-144

InVasc Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	INV-144
Sponsor	InVasc Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

INV-144 CI brief — competitive landscape report
INV-144 updates RSS · CI watch RSS
InVasc Therapeutics, Inc. portfolio CI